Prosecution Insights
Last updated: April 19, 2026

Examiner: SASAN, ARADHANA

Tech Center 1600 • Art Units: 1615 1654

This examiner grants 65% of resolved cases

Performance Statistics

64.7%
Allow Rate
+4.7% vs TC avg
1162
Total Applications
+25.9%
Interview Lift
1124
Avg Prosecution Days
Based on 1101 resolved cases, 2023–2026

Rejection Statute Breakdown

1.1%
§101 Eligibility
14.6%
§102 Novelty
44.4%
§103 Obviousness
17.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19335896 MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS Non-Final OA Flamel Ireland Limited
18613904 COMPOSITIONS COMPRISING BIOACTIVE GLASS AND AMINO ACID Non-Final OA CORNING INCORPORATED
18546602 AMORPHOUS FORM AND COMPOSITION CONTAINING SAID AMORPHOUS FORM Final Rejection OTSUKA PHARMACEUTICAL CO., LTD.
18690379 AQUEOUS COMPOSITION COMPRISING A FATTY DIALKYL ETHER, AN ANIONIC SURFACTANT WITH AT LEAST ONE CATIONIC COUNTERION AND A NONIONIC SURFACTANT Non-Final OA L'OREAL
18640463 METHOD OF PREPARING POUCH FILLING MATERIAL USING BINDER Non-Final OA KT&G Corporation
17801949 NON-CORROSIVE FORMULATION COMPOSITION FOR NITROGEN INHIBITORS Final Rejection Verdesian Life Sciences U.S., LLC
18093654 ORAL GEL COMPOSITIONS Non-Final OA Colgate-Palmolive Company
18291029 LIGHT-COLORED CATECHOL LIGNOSULFONATE SUNSCREEN MICROCAPSULE, AND PREPARATION THEREFOR AND USE THEREOF Non-Final OA South China University of Technology
18016189 COMPOSITIONS AND METHODS OF TREATING UPS-ASSOCIATED DISEASES Final Rejection Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
18697581 A Nano Emulsified Phyto-Drug For Transdermal Treatment of Diabetes Non-Final OA University of South Africa
18023119 COMPOSITION FOR AMELIORATING UNPLEASANT STATE CAUSED BY MENSTRUATION Non-Final OA ROHTO PHARMACEUTICAL CO., LTD.
18614077 LIPID NANOPARTICLES ENCAPSULATION OF LARGE RNA Non-Final OA Arcturus Therapeutics, Inc.
18585371 SUNSCREEN PREPARATION Non-Final OA BEIERSDORF AG
18681256 ANTIMICROBIAL COMPOSITIONS Non-Final OA Firmenich SA
18568202 DISSOLUTION RESISTANT TISSUE ADHERENT DRESSING APPLICATION AND ITS DELIVERY Non-Final OA TRICOL BIOMEDICAL, INC.
18573229 PHARMACEUTICAL COMPOSITIONS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR Non-Final OA Blueprint Mdeicines Coroporation
18568415 PHARMACEUTICAL COMPOSITION, PREPARATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF Non-Final OA WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.
18525295 COMPOSITIONS COMPRISING POROUS MICROPARTICLES AND METHODS OF USING THE SAME Non-Final OA WEST CHESTER UNIVERSITY
18564552 CO-AMORPHOUS FORMS FOR USE IN CANCER THERAPY Non-Final OA Zerion Pharma APS
18562212 ORODISPERSIBLE EFFERVESCENT TABLET COMPRISING BUDESONIDE FOR USE IN THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS Non-Final OA Dr. Falk Pharma GmbH
18283585 PHARMACEUTICAL COMPOSITION FOR IMPROVING CARDIAC FUNCTION Final Rejection CUORIPS INC.
18451355 Food Contact Disinfecting/Sanitizing Formulation And Wipe Final Rejection ARXADA, LLC
18467324 Compositions of Iboga Alkaloids and Methods of Treatment Non-Final OA Soneira Inc., P.B.C.
18447880 STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME Non-Final OA Amarin Pharmaceuticals Ireland Limited
18276396 INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF Non-Final OA Aerovate Therapeutics, Inc.
18272796 AMLODIPINE DRY SUSPENSION AND PREPARATION METHOD THEREFOR Non-Final OA APICHOPE BIO PHARMACEUTICAL CO., LTD.
18261679 AN AQUEOUS GEL COMPOSITION COMPRISING AN ETHYLCELLULOSE Non-Final OA DANISCO NUTRITION AND BIOSCIENCES INDIA PVT. LTD.
18318133 VETERINARY PHARMACEUTICAL FORMULATIONS Non-Final OA INCREVET, INC.
18251611 OPHTHALMIC COMPOSITION Non-Final OA IROMED GROUP S.R.L.
18033699 COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING SLEEP DISORDER OR INSOMNIA, CONTAINING EXTRACT OF ROASTED CITRUS BYPRODUCT AS ACTIVE INGREDIENT Final Rejection NUTRA-IT INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month